The role of the innate immune system in the development and treatment of hepatocellular carcinoma.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2020-01-31 DOI:10.2217/hep-2019-0007

Christoph Roderburg, Alexander Wree, Münevver Demir, Moritz Schmelzle, Frank Tacke

引用次数: 44

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Most patients present with advanced or metastatic HCC at diagnosis and face a dismal prognosis. Tyrosine kinases are the gold standard treatment for this disease but yield limited survival benefits. Immune checkpoint inhibitors that augment adaptive immunity have been tested in HCC. Complex interactions between tumor cells, lymphocytes and the tumor environment determine the efficacy of such immunotherapies. Innate immune mechanisms - known drivers of liver disease progression in pre-HCC conditions such as fibrosis or cirrhosis - may either support or counteract tumor-related immune activation. In this review, we will highlight current concepts of the role of the innate immune system in hepatocarcinogenesis and discuss their relevance for translation into clinics.

查看原文本刊更多论文

先天免疫系统在肝细胞癌发展和治疗中的作用。

肝细胞癌(HCC)是最常见的原发性肝癌。大多数患者在诊断时表现为晚期或转移性HCC，预后不佳。酪氨酸激酶是这种疾病的金标准治疗方法，但生存率有限。增强适应性免疫的免疫检查点抑制剂已经在HCC中进行了测试。肿瘤细胞、淋巴细胞和肿瘤环境之间复杂的相互作用决定了这种免疫疗法的疗效。先天免疫机制——已知的肝癌前期肝脏疾病进展的驱动因素，如纤维化或肝硬化——可能支持或抵消肿瘤相关的免疫激活。在这篇综述中，我们将重点介绍目前关于先天免疫系统在肝癌发生中的作用的概念，并讨论它们与临床转化的相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.